Bone Mineral Density Changes in Patients with Recent-Onset Rheumatoid Arthritis by Hafez, Eman A. et al.
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2011:4 87–94
doi: 10.4137/CMAMD.S7773
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Clinical Medicine Insights: Arthritis and 
Musculoskeletal Disorders
OrIgInAL reSeArCh
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2011:4  87
Bone Mineral Density changes in patients with Recent-Onset 
Rheumatoid Arthritis
eman A. hafez1, howaida e. Mansour1, Sherin h. hamza1, Sherine george Moftah2, Takwa Badr 
Younes3 and Mona Ahmed Ismail4
1Departments of Internal Medicine and rheumatology, 2radiodiagnosis, 3Physical Medicine, rheumatology and 
rehabilitation, 4Clinical Pathology, Ain Shams University, Cairo, egypt.  
Corresponding author email: howaida_mansour@hotmail.com
Abstract
Background: Osteoporosis and related fragility fractures are one of the most common complications seen in patients with rheumatoid 
arthritis (RA) and dramatically affect quality of life. 
Objective: To evaluate changes in bone mineral density in patients with recent onset rheumatoid arthritis (1 year) and its correlation 
if any with a modified DAS-28 score and simple erosion narrowing score (SENS).
Methods: This study included 30 patients with recent-onset rheumatoid arthritis fulfilling the new American College of Rheumatology/
European League Against Rheumatism diagnostic criteria for rheumatoid arthritis and 20 healthy volunteers as controls. All were sub-
jected to a complete blood count, erythrocyte sedimentation rate, C-reactive protein, liver function tests, renal function tests, rheuma-
toid factor, and plain x-rays of the hands and feet. Dual-energy x-ray absorptiometry DEXA was used to measure bone mineral density 
(BMD) of the left proximal femur, lumbar spine (L1–L4), and lower distal radius at the time of recruitment.
Results: In the RA patients, 13.3% had osteoporosis, 50% had osteopenia, and 36.7% had normal BMD. The most common site of osteo-
porosis was the lumbar spine (four patients, 13.3%) followed by the femur (two patients, 6.6%), and forearm (only one patient, 3.3%). 
There was a significantly higher percentage of osteoporosis among RA males than females and the difference was statistically   significant 
(P = 0.009). Osteoporosis was more common in patients treated with corticosteroids and disease modifying antirheumatic drugs (DMARDs) 
than in patients treated with only nonsteroidal anti-inflammatory drugs (P = 0.004). Higher disease activity (DAS-28) was found in RA 
patients with osteoporosis compared to RA patients with normal BMD or osteopenia, but the difference was not statistically significant. 
Osteoporotic RA patients were found to have a higher SENS score for radiological damage than nonosteoporotic ones.
Conclusion: BMD changes do occur in patients with early RA, and are not necessarily correlated with disease activity (DAS-28). 
However, a significant negative correlation was found between BMD and the score of radiological damage (SENS). Dual energy x-ray 
absorptiometry is an important investigation to assess BMD in early RA patients.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory 
autoimmune disease that causes chronic inflamma-
tion of the synovium with subsequent destruction and 
deformity of the joints. The etiology of RA remains 
unclear, but it is known to be associated with genetic 
and environmental factors.1 The prevalence of RA is 
  approximately 0.8% (0.3%–2.1%).2
Osteoporosis is more common in patients with RA 
than in the general population. The prevalence of con-
current osteoporosis is 50%. Osteoporosis can cause 
pain and loss of height, and increases the risk of frac-
tures after falling.3 The chronic synovial inflamma-
tion in RA can promote osteoclastogenesis, leading 
directly to both focal and generalized bone loss and 
increased risk of fractures. In addition, many indirect 
factors associated with inflammatory arthritis contrib-
ute to the risk of osteoporosis. These include immo-
bility, weight loss, and use of medications known to 
promote bone loss, such as glucocorticoids.4
The International Society for Clinical Densitometry 
(ISCD) and National Osteoporosis Foundation (NOF) 
has recommended dual-energy x-ray absorptiometry 
(DEXA) testing for all adults RA patients, as well as 
women over 65 years old , those who sustain fractures 
after the age of 50 years or suffer a fragility fracture, 
those on chronic glucocorticoids therapy, and anyone 
at high risk of low bone mass, bone loss, or fracture.5 
The aim of this study was to evaluate changes in bone 
mineral density (BMD) in patients with recent-onset 
RA (less than 12 months) and its correlation, if any, 
with RA disease activity and radiological joint dam-
age scores.
Methods
Study population
This  was  a  cross-sectional  case  control  study 
that  included  30  patients  with  recent  onset  RA 
(12 months) and 20 healthy age and sex matched 
  volunteers  as  controls.  All  patients  fulfilled  the 
  American College of Rheumatology/European League 
Against Rheumatism EULAR/ACR criteria for RA.6 
They were either inpatients in the Internal Medicine 
and Rheumatology Department or were attending the 
rheumatology outpatient clinic for regular follow-up 
at Ain Shams University Hospital. Informed consent 
was obtained from participants.
All  participants  underwent  full  history-taking 
and  a  thorough  physical  examination,  including  a 
detailed musculoskeletal assessment. Using the mod-
ified DAS-28 score to evaluate RA disease activity, 
a score # 2.6 was considered to be disease remission, 
2.6–3.2 as low disease activity, 3.3–4.9 as moderate 
disease activity, and .5.1 as severe disease activity.7 
We determined the DAS cutoff value according to the 
median DAS score for our patients. Functional class 
assessment was done using a validated Arabic version 
of the health assessment questionnaire (HAQ).8
Laboratory investigations were performed, includ-
ing a full blood count (CBC) , erythrocyte sedimenta-
tion rate (ESR, mm/hour) in the first hour, C-reactive 
protein (CRP, mg/dL), and complete urine analysis, 
with full blood chemistry, including renal and liver 
function tests. Rheumatoid factor (RF IgM, U/L) was 
measured using the Biotec RA factor latex aggluti-
nation slide for qualitative determination of RF in 
serum.
All RA patients underwent plain X-ray films on 
the hands, feet and wrists joints, with calculation of 
radiological  damage  using  SENS.  The  x-ray  films 
were examined by an expert radiologist. The SENS 
cutoff value was determined according to the median 
SENS score for the RA patients.9
BMD  was  measured  for  all  RA  patients  at  the 
Radiodiagnosis  Department  using  DEXA  at  the 
proximal  femur,  lumbar  spine  (L1–L4),  and  distal 
radius. A trained technician performed all scans using 
the same Lunar DEXA machine. The threshold for 
establishing a diagnosis of osteoporosis was based on 
the World Health Organization (WHO) definition, ie, 
BMD $2.5 standard deviations below the young adult 
mean (or T score # −2.5). Osteopenia was defined as 
BMD # −1.0 SD and . −2.5 SD from this mean, 
with low bone mass including all participants with 
osteopenia or osteoporosis.10
Statistical analysis
Analysis  of  data  was  done  using  the  Statistical 
  Program for Social Sciences version 12 (SPSS Inc, 
Chicago, IL). Values are expressed as mean ± standard 
deviation  differences  in  values  between  the  two 
groups and were analyzed using the unpaired t-test 
for numeric variables. The Chi-square test was used 
to  analyze  categorical  variables.  Correlations  were 
established using the Spearman correlation test (r). Bone mineral density changes in recent-onset rA 
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The Mann–Whitney test was used for nonparametric 
data. The Kruskal-Wallis test (F) was used to com-
pare more than two groups with regard to quantitative 
variables for nonparametric data. The difference was 
considered nonsignificant if P . 0.05, significant if 
P  0.05, and highly significant if P  0.001.
Results
Demographic data, DAS-28 score, HAQ score, SENS 
score, and ESR for the study subjects are summarized 
in Table 1. The 30 patients with RA (group 1) comprised 
20 females and 10 males, aged 23–54 (35.7 ± 7.6) years 
with a mean disease duration of 8.6 ± 3.6 months. The 
20 controls (group 2) comprised 17 (85%) females 
and three (15%) males aged 23–50 (mean 35.7 ± 7) 
years. Six (20%) patients in group 1 were smokers and 
two (10%) people in group 2 were smokers. Seventeen 
patients (56.6%) received non steroidal anti-inflamma-
tory drugs (NSAIDs) alone and 13 (43.3%) received 
steroids with disease-modifying antirheumatic drugs 
(DMARDS), with 12 receiving methotrexate and one 
receiving leflunamide.
Using  a  modified  DAS-28,  it  was  found  that 
5/30  RA  patients  (16.6%)  were  in  remission,  one 
patient (3.3%) was in a low disease activity, 17/30 
patients (56.6%) were in a moderate disease activity, 
and  7/30  patients  (23.3%)  were  in  a  high  disease 
activity (Table 1). HAQ scores showed that 24/30 
(80%)  of  the  RA  patients  had  mild  functional 
disability  (score  0–1),  5/30  (16.7%)  had  moderate 
disability  (score  1–2),  and  one  patient  (3.3%)  had 
severe disability (score 2–3, Table 1).
Radiological  assessment  of  joint  damage  in  RA 
patients showed a SENS score of 0–31.4 (11.7 ± 9.7), 
Table 1. On DEXA scanning, 15 (50%) RA patients 
had  osteopenia  and  four  (13.3%)  had  osteoporosis 
at the   lumbar spine. In the control group, two (10%) 
had  osteopenia  at  the  lumbar  spine,  and  none  had 
  osteoporosis. Fisher’s Exact test showed that RA patients 
had a significantly higher frequency of osteoporosis and 
osteopenia than controls (P  0.05, Table 2).
Comparison  of  risk  factors  for  osteoporosis 
between  patients  and  controls  revealed  no  statisti-
cally significant (P . 0.05) regarding age,   gender, 
and  smoking.  However,  routine    laboratory  tests 
showed a highly statistically significant difference in 
ESR (P  0.001, Table 1) between the groups. Other 
routine laboratory tests, including kidney and liver 
function tests, and complete blood count did not show 
any statistically significant differences.
Osteoporosis  was  significantly  more  common 
in  males  than  in  females  (P  =  0.009)  at  all  sites, 
ie, lumbar spine, femur, and forearm (P  0.001). 
Furthermore,  osteoporosis  was  significantly  more 
Table 1. Demographic, clinical, and laboratory data in 30 patients with rheumatoid arthritis versus controls.
Variables RA cases (n = 30) controls (n = 20) P sig
Age (years) mean ± SD 35.7 ± 7.6 (23–54) 35.7 ± 7 .0.05 nS
gender Male 
Female
10/30 (33.3%) 
20/30 (66.7%)
3 (15%) 
17 (85%)
.0.05 nS
Smoking no 
Yes
24/30 (80%) 
6/30 (20%)
18 (90%) 
2 (10%)
.0.05 nS
Disease duration (mean ± SD) and range (months) 8.6 ± 3.6 (2–12)
Drug intake nSAIDS only 17/30 (56.6)
Combination of cortisone and DMArDS 13/30 (43.3%)
DAS-28 remission (#2.4) 5/30 (16.6%)
Mild disease activity (2.5–3.6) 1/30 (3.3%)
Moderate disease activity (3.7–5.5) 17/30 (56.6%)
Severe disease activity (.5.5) 7/30 (23.3%)
hAQ 0–1 (mild disability) 24/30 (80%)
.1–2 (moderate disability) 5/30 (16.7%)
.2–3 (severe disability) 1/30 (3.3%)
SenS score (mean ± SD) 11.7 ± 9.7 (0–31.4)
eSr mm/hour (mean ± SD) 56.5 ± 31 (10–120) 12 ± 4 0.001 hS
Abbreviations: DAS-28, Disease Activity Scale-28; hAQ, health Assessment Questionnaire; SenS, simple erosion narrowing score; eSr, erythrocyte 
sedimentation rate; DMARDS, disease-modifying antirheumatic drugs; NS, not statistically significant; HS, highly statistically significant; Sig, statistical 
significance; RA, rheumatoid arthritis.hafez et al
90  Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2011:4
common in patients treated with corticosteroids and 
DMARDs compared with those treated with NSAIDs 
alone (P = 0.004) and this was mainly in the t score 
for the lumbar spine and femur (P  0.05). Osteo-
porosis was also more common in RA patients who 
smoked (2/6 [33.3%]) compared with those who did 
not smoke (2/24 [8.3%]) but the difference was not 
statistically significant (P = 0.2, Table 3).
By HAQ score, 3/4 (75%) RA patients with osteo-
porosis had severe disability (HAQ 3), while 7/15 
(46.7%) patients with osteopenia had moderate dis-
ability  (HAQ  2).  Furthermore,  11/30  RA  patients 
had normal BMD, of whom four with mild disability 
(HAQ 1), seven had moderate disability, and none had 
severe disability. This indicates that there was signifi-
cant disability (increased HAQ score) consistent with 
lower BMD in subgroups of RA patients according 
to HAQ score and the difference was statistically sig-
nificant (P = 0.02, Table 3). More RA patients with 
osteoporosis had an elevated DAS-28 score than those 
with normal BMD or osteopenia, but the difference 
was not statistically significant (P = 0.4, Table 3). 
Significantly more RA patients with osteoporosis had 
elevated SENS than those having normal BMD or 
osteopenia (P = 0.03, Table 3). Higher SENS were 
found in RA patients with high ESR than in those 
with low ESR, but the difference was not statistically 
significant (P = 0.7).
Four out of 19 CRP-positive RA patients had osteo-
porosis and no none of the CRP-negative RA patients 
had  osteoporosis.  Seven  of  the  19  CRP-  positive 
patients were found to be osteopenic, ie, BMD was 
lower  in  CRP-positive  RA  patients  than  in  CRP-
  negative patients, and the difference was   statistically 
significant (P  0.05, Table 3).   However, on   comparing 
RF-positive and CRP-negative RA patients with regard 
to BMD (t and z scores at different sites), there was no 
statistically significant   difference (P . 0.05).
There  was  no  statistically  significant  correlation 
was found between disease duration, ESR, DAS-score 
and BMD at any anatomical site (P . 0.05). However, 
there was a statistically significant negative correlation 
between SENS score and BMD at the lumbar spine 
(r = −0.054, P  0.01). Moreover, we found a signifi-
cant negative correlation between BMD and HAQ score 
(r = −0.425 and P = 0.019, Table 4 and Fig. 2).
Discussion
Osteoporosis and fragility-related fractures are one of 
the most common complications seen in patients with 
RA and dramatically affect quality of life.11 The pres-
ent study was designed to evaluate BMD changes in 
patients with recent-onset RA, as well as the effect 
of inflammation, mobility, and drugs  (steroids and 
DMARDS) on these changes.
Our results support the association between early RA 
and osteoporosis. We found that 13.3% of our patients 
with early RA had osteoporosis, 50% had osteopenia, 
Table 2. Comparison of bone mineral density at three anatomical sites between patients with rheumatoid arthritis and 
controls.
t score RA patients (n = 30) controls (n = 20)
normal BMD 
(n = 11)
Osteopenia  
(n = 15)
Osteoporosis  
(n = 4)
normal BMD  
(n = 18)
Osteopenia  
(n = 2 )
Osteoporosis   
(n = 0)
Lumbar spine  
(L1–L4)
13/30 43.3% 13/30 43.3% 4/30 13.3% 18/20 90% 2/20 10% 0  0%
Left radius 22/30 73.3% 7/30 23.3% 1/30 3.3% 20/20 100% 0 0% 0 0%
Left femur 22/30 73.3% 6/30 20% 2/30 6.6% 20/20 100% 0 0% 0 0%
notes: BMD: normal (t score . −1), osteopenia (t score # −1.0 . −2.5), osteoporosis (t score # −2.5). 50% of rA patients were found to have osteopenia 
while only 10% of controls were osteopenic (P  0.05).
Abbreviations: BMD, bone mineral density; rA, rheumatoid arthritis.
Controls Cases
0
20
40
60
80
100
Normal OsteopeniaO steoprosis
Figure 1. Comparison of bone mineral density between patients with 
rheumatoid arthritis and controls.Bone mineral density changes in recent-onset rA 
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and 36.7% had normal BMD, while none of the control 
subjects had osteoporosis. Only two controls (10%) had 
osteopenia, and 18 control subjects (90%) had normal 
BMD. These findings are in agreement with those of 
Brand et al12 who reported that patients with RA have a 
higher risk of low BMD than normal age- and gender-
matched populations. Similarly, a study reported by 
Kim et al13 showed an increased risk of osteoporotic 
fractures in RA patients in all age groups, regardless 
of gender, and at various anatomical sites compared 
with individuals without RA. In   contrast, Curtis et al14 
found that the proportion of their RA patients meeting 
t score criteria for osteoporosis (t score # −2.5 at either 
the lumbar spine or femoral neck) was only 4%, and 
Yoon et al15 reported that 52% of their patients with 
early-onset RA had osteoporosis and 39% were classi-
fied as having osteopenia.
In the present study, we found that the most com-
mon site for osteoporosis in our RA patients was the 
lumbar spine (four patients [13.3%]), followed by the 
Table  3.  Comparison  of  BMD  between  patients  with  rheumatoid  arthritis  having  low  versus  high  DAS  score,  hAQ,   
SenS, CrP.
normal BMD  
(n = 11)
Osteopenia 
(n = 15)
Osteoporosis 
(n = 4)
χ2/F P
Age (mean + SD), years 33.3 ± 6.4 36.3 ± 6.0 40.0 ± 14.6 1.2 0.3 
nS
Disease duration (mean + SD), years 8.5 ± 3.6 8.2 ± 4.0 10.2 ± 1.7 0.4 0.6 
nS
gender Female (n = 20) 9 (45%) 11 (55%) 0 9.4 0.009*
hS Males (n = 10) 2 (20%) 4 (40%) 4 (40%)
Drug intake nSAIDS only (n = 17) 7 (41.2%) 10 (58.8%) 0 (0%) 11.1 0.004 
hS Corticosteroids and DMArDs (n = 13) 4 (30.8%) 5 (38.5%) 4 (30.8%)
Smoking Smokers ( n = 6) 1 (16.7%)
10 (41.7%)
3 (50%)
12 (50%)
2 (33.3%)
2 (8.3%)
3.0 0.2
nS nonsmoker (n = 24)
DAS-28 Low DAS (n = 15) 6 ( 54.5%)
5 (45.5%)
8 (53.3%)
7 (46.7%)
1 (25%)
3 (75%)
0.6 0.4
nS high DAS (n = 15)
hAQ 0–1 (mild disability) 4 (36.4%) 5 (33.3%) 0 10.5 0.02 S
.1–2 (moderate disability) 7 (63.3%) 7 (46.7%) 1 (25%)
.2–3 (severe disability) 0 3 (20%) 3 (75%)
SenS score Low SenS (n = 13) 7 (63.6%) 6 (40%) 0 4.6 0.03 S
high SenS (n = 17) 4 (36.4%) 9 (60%) 4 100%
CrP (mg/dL) CrP-positive (n = 19) 8 (73%) 7 (47%) 4 100% 3.5 0.05 S
CrP-negative (n = 11) 3 (27%) 8 (53%) 0
note: DAS-28 score cutoff value was 4.35 and SenS score cutoff value was 11.6%.
Abbreviations: BMD, bone mineral density; DAS-28, Disease Activity Scale-28; hAQ, health Assessment Questionnaire; SenS, simple erosion narrowing 
score; CRP, C-reactive protein; DMARDS, disease-modifying antirheumatic drugs; NS, not statistically significant; HS, highly statistically significant;   
S, statistically significant; RA, rheumatoid arthritis; NSAIDs, nonsteroidal anti-inflammatory drugs; SD, standard deviation.
Table 4. Correlations between t scores, z scores, and various clinical parameters in patients with rheumatoid arthritis.
BMD 
t and z scores
esR Disease  
duration 
DAs  
score 28 
sens score  HAQ 
r p r p r p r p r p
t score lumbar spine −0.09 .0.05 −0.18 .0.05 −0.14 .0.05 −0.54 0.001 −0.425 0.05
t score radius −0.007 .0.05 −0.15 .0.05 −0.07 .0.05 −0.18 .0.05 −0.251 0.05
t score femur −0.12 .0.05 −0.10 .0.05 −0.20 .0.05 −0.13 .0.05 −0.360 0.05
z score lumbar spine 0.11 .0.05 0.011 .0.05 −0.08 .0.05 0.15 .0.05 – –
z score radius 0.17 .0.05 0.07 .0.05 −0.10 .0.05 −0.13 .0.05 – –
z score femur −0.01 .0.05 −0.02 .0.05 −0.24 .0.05 −0.19 .0.05 – –
Abbreviations: BMD, bone mineral density; DAS-28, Disease Activity Scale-28; hAQ, health Assessment Questionnaire; SenS, simple erosion narrowing 
score; eSr, erythrocyte sedimentation rate.hafez et al
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femur (two patients [6.6%]), with involvement of the 
forearm in only one patient (3.3%). We also found that 
only two of 20 (10%) control subjects had osteope-
nia which affected the lumbar spine. These findings 
are consistent with those of Güler-Yüksel et al16 who 
reported that the most common site for osteoporosis in 
patients with early RA was the spine (9%), followed 
by the total hip (4%), with 11% of cases occurring at 
either the spine or the hip. The proportion of patients 
with decreased BMD was 19% for the spine, 14% for 
the hip, and 25% for either the spine or the hip. Yoon 
et al15 showed that osteoporosis was slightly more prev-
alent at the lumbar spine than at the femur in women 
with RA who were younger than 60 years of age, but 
the difference was not statistically significant.
We found that 22/30 (73.3%) of our RA patients 
had normal BMD at the femoral neck, six (20%) had 
osteopenia, and two (6.6%) had osteoporosis. These 
findings are similar to that reported by Curtis et al14 who 
found that the majority of their RA patients had normal 
t scores at the femoral neck (t score . −1.0) while the 
remainder had femoral neck t scores  −1.0 but . −2.0, 
and none had osteoporosis. In our RA cohort, 43.3% had 
normal BMD, 43.3% had osteopenia, and 13.3% had 
osteoporosis at the lumber spine. Zhang et al17 found 
that 38.6% of their subjects had either osteopenia or 
osteoporosis at the lumbar spine, and 44.9% had either 
osteopenia or osteoporosis at the femoral neck.
Interestingly, in the present study, osteoporosis was 
more common in RA men (40%) than in women (0%) 
with RA, and this difference was highly   statistically 
significant  (P    0.01).  This  might  be  due  to  the 
  natural protective effect of estrogen hormone against 
the occurrence of osteoporosis Meanwhile, osteopenia 
were significantly (P  0.01) more common in female 
RA patients (55%) than in males (40%). Güler-Yüksel 
et al16 found similar results, reporting reduced BMD 
in men with RA than in their female counterparts. 
However, the study reported by Yoon et al15 showed 
that when patients with RA were grouped by gender, 
the prevalence of osteoporosis in women was 57%, 
whereas men had a prevalence of only 28%.
Furthermore,  our  RA  patients  with  osteoporosis 
were older and had a longer disease duration than 
those without osteoporosis, but the difference was not 
statistically significant (P . 0.05). These findings are 
similar to those of Sinigaglia et al18 who found that 
RA patients with spine or femoral osteoporosis had a 
significantly longer disease duration. Our results are 
also consistent with those of Güler-Yüksel et al16 who 
reported that RA patients with early, active, erosive 
disease and a positive rheumatoid factor had more 
aggressive joint disease and decreased BMD.
In  the  present  study,  we  found  a  significantly 
lower  BMD  in  RA  patients  who  received  steroids 
and DMARDS compared with those who received 
NSAIDS alone (P = 0.004). This might be explained 
by the fact that the introduction of NSAIDS as lone 
treatment  for  RA  occurs  very  early,  even  before 
definitive diagnosis of the disease, ie, at a time when 
BMD  would  still  be  normal.  However,  we  would 
expect normalization of BMD after controlling   disease 
activity in patients with known RA who are treated 
with corticosteroids and DMARDS, given the widely 
recognized  osteoporotic  effect  of  corticosteroids. 
  However, Curtis et al14 stated that there was no asso-
ciation between glucocorticoid use and BMD.
Additionally,  we  found  that  osteoporosis  in  RA 
patients was more common in smokers than in non-
smokers, but the difference was not statistically signifi-
cant (P = 0.2), and this finding was in agreement with 
that of Lorentzon et al19 who reported that smokers had 
significantly lower BMD on DEXA than nonsmokers.
We  have  also  found  that  osteoporosis  was  sig-
nificantly  more  common  in  CRP-positive  than  in 
  CRP-negative  RA  patients  (P    0.05),  but  there 
was no significant difference in BMD between RF-
positive and RF-negative patients (P . 0.05). Kinjo 
et al20 found that in patients with RA, reduced BMD 
SENS score
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Figure 2. Significant negative correlation between t score at lumbar spine 
and SenS in patients with rheumatoid arthritis (r = −0.54, P  0.001).Bone mineral density changes in recent-onset rA 
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tended to be seen with CRP . 1 mg/dL and a positive 
rheumatoid factor (RF) in female patients. However, 
none of these findings reached statistical significance. 
Kim et al14 also observed an increased risk of osteo-
porosis associated with a positive RF and elevated 
acute phase reactants, although this was not statisti-
cally significant. While Solomon et al,21 have found 
that BMD at the total hip was significantly lower in 
rheumatoid factor-positive women than in rheuma-
toid factor-negative women. However, values at the 
lumbar spine were almost identical for rheumatoid 
factor-positive and -negative women.
Regarding HAQ score, we have found that most of 
RA patients with osteoporosis have severe functional 
disability  (HAQ  3)  (P  =  0.02).  Similarly,  Sinigaglia 
et al18 found that patients with spinal or femoral osteopo-
rosis had a significantly higher HAQ score (P = 0.001).
In our study RA patients with osteoporosis were 
found  to  have  a  higher  SENS,  indicative  of  radio-
logical  damage  than  non  osteoporotic  RA  patients 
In another way significantly lower BMD was found 
in RA patients with higher SENS than in those with 
a lower SENS (P = 0.03). These findings support the 
hypothesis of a common pathologic mechanism for 
generalized bone loss and localized radiographic joint 
damage in RA patients. Similar data were reported by 
Lodder et al22 who found significant radiological dam-
age in RA patients with low BMD at the hip, in contrast 
with Güler-Yüksel et al16 who found that DAS, HAQ, 
and SENS scores were not correlated with BMD at the 
spine or hip in RA patients. A higher SENS in our RA 
patients was not correlated with RF status (P = 0.9). 
Courvoisier et al23 found that the radiographic Sharp 
score at 10 years was correlated significantly with base-
line ESR, IgA, RF and baseline radiographic scores 
(including erosion, joint narrowing, and total scores).
We found a higher incidence of osteoporosis in 
patients with a high DAS-28 score compared with 
those with a low DAS-28 score, but the difference 
was not statistically significant (P = 0.4). This was 
in agreement with Brand et al,12 the DAS-28 score 
was  not  corrrelated  with  BMD.  Similarly,  Curtis 
et al14 reported that there were no associations of RA 
activity, severity, or erosions with BMD at either site 
on univariate or multivariate analysis.
Moreover, we found that there was no correlation 
between  ESR  and  BMD  at  different  sites  (lumbar 
spine, r = −0.09; radius, r = −0.007; femur, r = −0.12, 
P . 0.05), while Cortet et al24 found that at femoral 
neck BMD was significantly inversely correlated with 
ESR, age and HAQ score. These differences might be 
due to different patients’ cohort as our RA patients 
have early RA and longer periods of follow up were 
needed to establish these possible correlations.
In our study, we found a statistically significant 
inverse correlation between SENS and BMD only- at 
the lumbar spine (r = −0.54, P  0.001). This may 
be due to the fact that the vertebral bodies contain 
more trabecular bone than the hip, the trabecular bone 
is more metabolically active, so one might anticipate 
that perturbations in cytokines related to RA would 
affect BMD at the lumbar spine more dramatically 
than in the hip. In contrast, Solomon et al21 found 
that in RA there was a significant correlation between 
erosions and total hip BMD more than at the lum-
bar spine. Several potential explanations exist for this 
apparent discrepancy. It is possible that the inflamma-
tory process underlying RA affects BMD at the hip 
more than at the lumbar spine. Also, total hip BMD 
may more closely relate to joint mobility and overall 
functional status than lumbar spine BMD.
Finally,  we  found  that  there  was  a  significant 
positive  correlation  between  HAQ  and  DAS-28 
(P = 0.000) and between HAQ and SENS (P = 0.01). 
These were in accordance with Courvoisier et al23 
who found that HAQ scores were strongly associated 
with disease activity parameters, as DAS-28. Only 
erosion score was weakly but significantly associated 
with HAQ score. Van der Heijde et al25 reported that 
HAQ scores tended to increase with increasing radio-
graphic progression.
We concluded that BMD changes do occur early 
in patients with RA, they are not necessarly corre-
lated with clinical disease activity, as it can occur 
in patients with mild disease activity. There was a 
significant correlation between radiographic damage 
and  reduced  bone  mass.  DEXA  is  an  important 
diagnostic tool for detecting osteoporosis in patients 
with early RA, serving as a promising supplement to 
x-ray scoring methods.
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